Neuroendocrine Tumor Treatment Market in India

Neuroendocrine Tumor Treatment in India Trends and Forecast

The future of the neuroendocrine tumor treatment market in India looks promising with opportunities in the hospital and clinic markets. The global neuroendocrine tumor treatment market is expected to grow with a CAGR of 10.2% from 2025 to 2031. The neuroendocrine tumor treatment market in India is also forecasted to witness strong growth over the forecast period. The major drivers for this market are the growing prevalence of neuroendocrine cancer, the technological developments in the field of treating neuroendocrine tumors, and the increase in government programs.

• Lucintel forecasts that, within the product category, somatostatin analogs (SSAs) are expected to witness the highest growth over the forecast period.
• Within the end use category, hospital is expected to witness higher growth due to the existence of advanced technologies and a variety of NET diagnosis alternatives.

Emerging Trends in the Neuroendocrine Tumor Treatment Market in India

The neuroendocrine tumor (NET) treatment market in India is evolving rapidly, with advancements in both diagnostic technologies and treatment options. The growing awareness of NETs and the availability of cutting-edge therapies are enhancing survival outcomes for patients. Emerging trends such as the use of targeted therapies, improved imaging techniques, and greater access to novel treatments are driving change. With an increasing focus on personalized medicine and multidisciplinary care, India is witnessing a transformation in the approach to NET treatment, leading to better clinical results.

• Rise in Targeted Therapies for NETs: Targeted therapies such as everolimus and sunitinib are being increasingly used to treat NET patients in India. These therapies specifically target the molecular pathways responsible for tumor growth, offering patients a more effective and less toxic alternative to traditional chemotherapy. The introduction of these therapies has led to improved survival rates, especially in patients with metastatic NETs. The availability and adoption of targeted treatments are significantly enhancing the management of NETs in India, with better disease control and fewer side effects.
• Growing Adoption of Peptide Receptor Radionuclide Therapy (PRRT): Peptide Receptor Radionuclide Therapy (PRRT) is gaining traction in India as a highly effective treatment for advanced or metastatic NETs. This targeted therapy uses radiolabeled peptides to deliver radiation directly to the tumor, minimizing damage to surrounding healthy tissues. The therapy has shown significant efficacy in controlling tumor progression and improving the quality of life for patients with difficult-to-treat NETs. With more hospitals offering PRRT, it is expected to become a standard treatment option for NET patients in India, leading to better management of advanced stages.
• Increased Focus on Early Detection through Advanced Imaging: The emphasis on early detection of NETs is growing in India, driven by the development of advanced diagnostic tools such as Ga-68 PET/CT scans. These imaging techniques allow for the precise localization and staging of NETs, enabling earlier intervention and personalized treatment plans. Early detection plays a critical role in improving patient outcomes by facilitating prompt treatment and better management of the disease. As these imaging technologies become more widespread in India, they are expected to enhance the prognosis for NET patients across the country.
• Expansion of Multidisciplinary Treatment Approaches: In India, a multidisciplinary approach to treating NETs is becoming more prevalent, involving collaboration among oncologists, endocrinologists, radiologists, and surgeons. This team-based approach ensures that each patient receives personalized care tailored to their specific condition. Multidisciplinary teams are able to address various aspects of the disease, from diagnosis to treatment and follow-up care, improving the overall quality of care. The adoption of this holistic approach is helping to improve the survival and well-being of NET patients in India.
• Increasing Use of Immunotherapy in Clinical Trials: Immunotherapy, which stimulates the immune system to target cancer cells, is showing potential in treating NETs in India. Although still in the clinical trial phase, therapies like checkpoint inhibitors are gaining attention for their ability to improve the body’s immune response against NETs. These therapies offer hope for patients who have exhausted other treatment options. As research and clinical trials continue, immunotherapy could become an essential component of the treatment regimen for NETs in India, providing more options for patients with advanced disease.

Emerging trends such as the increasing use of targeted therapies, the growing adoption of Peptide Receptor Radionuclide Therapy (PRRT), advances in diagnostic imaging, the rise of multidisciplinary care teams, and the exploration of immunotherapy are significantly reshaping the neuroendocrine tumor treatment market in India. These developments are driving improvements in diagnosis, treatment options, and patient outcomes. With these advancements, the management of NETs is becoming more precise, personalized, and effective, offering hope for better survival rates and quality of life for patients in India.

Recent Developments in the Neuroendocrine Tumor Treatment Market in India

The treatment landscape for Neuroendocrine Tumors (NETs) in India has evolved with the introduction of new therapies, improved diagnostic methods, and the adoption of multidisciplinary care models. The focus on early detection and the increasing use of advanced treatments have led to better patient outcomes. With a greater emphasis on personalized medicine, these developments are significantly improving the management of NETs, particularly for patients with advanced disease stages. India’s NET treatment market is progressing toward more effective and comprehensive care.

• Introduction of Targeted Drugs like Everolimus: The use of targeted drugs like everolimus is gaining prominence in India for the treatment of NETs. This drug inhibits the mTOR pathway, which is responsible for cancer cell growth. Everolimus is particularly effective in controlling tumor progression in advanced NETs, improving patient outcomes significantly. Its ability to target specific tumor mechanisms reduces the side effects typically associated with traditional chemotherapy, offering a more manageable treatment option. As more patients in India have access to everolimus, it is expected to play a crucial role in the future of NET care.
• Wider Availability of PRRT for Metastatic NETs: Peptide Receptor Radionuclide Therapy (PRRT) is becoming more accessible to NET patients in India, particularly for those with advanced metastatic tumors. PRRT involves delivering radioactive peptides directly to tumor cells, enabling precise tumor targeting with minimal damage to healthy tissue. The expansion of PRRT treatment centers in India has led to significant improvements in tumor control and overall patient survival. With growing availability, PRRT is set to become a standard treatment for advanced NETs, offering new hope to patients with limited treatment options.
• Focus on Early Detection through Ga-68 PET/CT Scanning: India is witnessing an increased focus on early detection of NETs, with advanced imaging techniques like Ga-68 PET/CT scans becoming more widely available. These imaging tools enable precise tumor localization and staging, making it possible to detect NETs at earlier, more treatable stages. Early detection plays a critical role in improving prognosis by facilitating timely intervention. As access to advanced imaging technology increases across India, earlier and more accurate diagnosis will lead to improved treatment outcomes for NET patients.
• Rise of Multidisciplinary Treatment Teams: In India, the multidisciplinary care model is being widely adopted for NET treatment. This approach involves collaboration among oncologists, surgeons, endocrinologists, and radiologists to create personalized treatment plans for patients. Multidisciplinary teams offer a more comprehensive and coordinated approach to treatment, improving clinical outcomes. The increasing use of this collaborative model ensures that all aspects of patient care—diagnosis, treatment, and follow-up—are optimized, leading to better management of NETs and enhanced patient quality of life in India.
• Expanding Role of Immunotherapy in Clinical Trials: Immunotherapy, which harnesses the body’s immune system to target and destroy cancer cells, is emerging as a potential treatment option for NETs in India. While still in the clinical trial phase, therapies such as immune checkpoint inhibitors are showing promise in treating NET patients, especially those who have not responded to other treatments. As research progresses, immunotherapy could play an important role in the future management of NETs, providing more treatment options for patients with advanced or refractory disease.

Recent developments in the neuroendocrine tumor treatment market in India, such as the introduction of targeted drugs, the wider availability of PRRT, advances in diagnostic imaging, the rise of multidisciplinary care, and the exploration of immunotherapy, are transforming the approach to NET management. These advancements are improving diagnosis, treatment precision, and overall patient care, ensuring better outcomes for patients across India. As these developments continue to evolve, the future of NET treatment in India looks promising, offering enhanced survival rates and quality of life for patients.

Strategic Growth Opportunities for Neuroendocrine Tumor Treatment Market in India

India’s neuroendocrine tumor (NET) treatment market is expanding rapidly, driven by advances in medical technologies, increasing healthcare access, and growing awareness of rare cancers. As the demand for advanced therapies increases, there are significant opportunities for growth across various treatment areas. These opportunities not only promise to improve patient outcomes but also contribute to the overall development of India’s healthcare system. The following are five key growth opportunities shaping the future of the NET treatment market in India.

• Expansion of Targeted Therapies: Targeted therapies, which focus on specific molecular targets in tumor cells, are gaining traction in India. As more NET patients are diagnosed and treated, these therapies are offering effective alternatives to traditional treatments, minimizing side effects while improving treatment efficacy. The development and use of targeted therapies are crucial in improving survival rates for patients with advanced NETs in India. This shift toward personalized medicine is likely to be a key growth driver for the NET treatment market, offering tailored treatment options.
• Increasing Utilization of Peptide Receptor Radionuclide Therapy (PRRT): Peptide receptor radionuclide therapy (PRRT) is showing considerable promise in India for the treatment of advanced NETs. This technique delivers targeted radiation to cancerous cells, reducing tumor size and improving patient prognosis. As more hospitals adopt PRRT, it will increase treatment options available to Indian patients with metastatic NETs. With growing awareness and research into its efficacy, PRRT is poised to become a major treatment modality in India’s NET market, contributing to better management and improved patient outcomes.
• Advancements in Immunotherapy: Immunotherapy is making waves in the treatment of various cancers, including neuroendocrine tumors. In India, ongoing research and clinical trials are investigating the potential of immune checkpoint inhibitors and other immunotherapeutic agents for NETs. These therapies work by boosting the immune system’s ability to target and destroy cancer cells. As clinical evidence grows, immunotherapy is expected to be increasingly integrated into treatment regimens, offering a new and promising option for NET patients in India, particularly those with limited treatment options.
• Early Diagnosis through Biomarker Development: The development of biomarkers for early diagnosis is an emerging growth opportunity in India’s NET treatment market. Early detection is crucial for improving patient survival rates and reducing the cost of long-term treatments. With advanced diagnostic techniques such as biomarker tests and enhanced imaging, India is improving its ability to diagnose NETs at an earlier stage. This is leading to better treatment outcomes and more cost-effective management of the disease, significantly contributing to the growth of the NET treatment market.
• Growth in Clinical Trials and Research Collaborations: India is witnessing an increase in clinical trials and international research collaborations aimed at developing new therapies for neuroendocrine tumors. By participating in global clinical trials, India is accelerating the introduction of new treatments, including innovative drug therapies and treatment modalities. Collaborative efforts between Indian pharmaceutical companies, research institutions, and global biotech firms are helping bring advanced therapies to the Indian market. These collaborations are expected to drive future growth and expand treatment options for NET patients.

The neuroendocrine tumor treatment market in India is set for substantial growth, fueled by advances in targeted therapies, peptide receptor radionuclide therapy, immunotherapy, early diagnosis, and increasing clinical trials. These opportunities are expanding treatment options, improving patient care, and paving the way for the development of more personalized therapies. As India continues to strengthen its healthcare infrastructure and focus on innovative treatments, the NET treatment market will evolve, providing better outcomes for patients across the country.

Neuroendocrine Tumor Treatment Market in India Driver and Challenges

The neuroendocrine tumor treatment market in India is influenced by several technological, economic, and regulatory factors. Key drivers include advancements in medical technology, growing healthcare access, and rising awareness about rare cancers. However, challenges such as high treatment costs, limited access to specialized care, and regulatory barriers remain significant. Addressing these factors is crucial to unlocking the market’s potential. Below are the main drivers and challenges impacting this market.

The factors responsible for driving the neuroendocrine tumor treatment market in India include:
• Advancements in Medical Technology: Advancements in medical technology, particularly in diagnostic imaging and therapeutic devices, are propelling the NET treatment market in India. The adoption of state-of-the-art equipment like positron emission tomography (PET) scanners and improved radiation therapy techniques is helping in better tumor detection and more effective treatments. These innovations not only improve patient outcomes but also contribute to the overall quality of healthcare services in India, driving market growth.
• Increased Awareness and Early Detection: There is growing awareness of neuroendocrine tumors in India, which is leading to earlier diagnoses and more timely interventions. With greater education on the symptoms and potential risks of NETs, more people are seeking medical help at the onset of symptoms. Early detection is critical for improving survival rates, and it is expected that more accessible diagnostic technologies will further accelerate this trend, thereby driving growth in the market.
• Rising Healthcare Investments: India is witnessing significant investments in its healthcare sector, with an increasing focus on cancer treatment, including NETs. These investments are supporting the development of more specialized treatment centers, increasing access to cutting-edge therapies, and enhancing patient care. As healthcare infrastructure improves, more patients will have access to the latest treatment options, contributing to the expansion of the NET treatment market.
• Growing Demand for Personalized Medicine: Personalized medicine is gaining popularity in India, especially for complex diseases like neuroendocrine tumors. As India’s healthcare system becomes more patient-centric, treatments that are tailored to an individual’s specific tumor profile will become increasingly common. This shift towards personalized therapies, such as targeted therapies and immunotherapies, is expected to drive growth in the market by offering more effective and less invasive treatment options for NET patients.
• Government Support and Policy Initiatives: The Indian government’s focus on improving access to healthcare and offering support for cancer treatments is another key driver for the NET treatment market. Government policies aimed at subsidizing treatment costs and improving access to advanced cancer therapies are crucial in addressing the needs of NET patients. These initiatives will help reduce financial barriers to treatment and expand market growth.

Challenges in the neuroendocrine tumor treatment market in India are:
• High Treatment Costs: High treatment costs remain a significant barrier to accessing neuroendocrine tumor therapies in India. While newer treatments show promise, their affordability is often a concern for patients, particularly in low-income regions. The cost of therapies like immunotherapy and targeted treatments can be prohibitive, limiting patient access. Addressing this challenge through cost reductions or improved reimbursement systems is essential to ensure broader access to NET treatments.
• Limited Access to Specialized Care: Although India is home to a number of world-class medical institutions, specialized care for neuroendocrine tumors remains concentrated in urban areas. Patients in rural regions face challenges in accessing proper diagnosis and treatment. Expanding specialized NET care across the country is essential to ensure that all patients, regardless of location, have access to timely and effective treatments, thereby driving market growth.
• Regulatory Barriers to New Treatments: The approval process for new treatments in India can be slow and complex. While the Indian government is working to streamline drug approvals, regulatory barriers can delay the introduction of new therapies. This impacts the timely availability of cutting-edge treatments for NET patients. Reducing regulatory delays and accelerating approval processes will be crucial for market growth and patient access to innovative therapies.

The neuroendocrine tumor treatment market in India is growing steadily, driven by advancements in medical technology, increased awareness, and rising healthcare investments. However, challenges such as high treatment costs, limited access to specialized care, and regulatory delays need to be addressed for the market to reach its full potential. With continued support from the government, investment in research, and improved healthcare infrastructure, India’s NET treatment market is poised for significant expansion, offering new hope for patients with neuroendocrine tumors.

List of Neuroendocrine Tumor Treatment Market in India Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies, neuroendocrine tumor treatment companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the neuroendocrine tumor treatment companies profiled in this report include:
• Company 1
• Company 2
• Company 3
• Company 4
• Company 5
• Company 6
• Company 7
• Company 8
• Company 9
• Company 10

Neuroendocrine Tumor Treatment Market in India by Segment

The study includes a forecast for the neuroendocrine tumor treatment market in India by product, indication, and end use.

Neuroendocrine Tumor Treatment Market in India by Product [Analysis by Value from 2019 to 2031]:

• Somatostatin Analogs (SSAs)
• Targeted Therapy
• Chemotherapy

Neuroendocrine Tumor Treatment Market in India by Indication [Analysis by Value from 2019 to 2031]:

• Lung
• Pancreas
• Gastrointestinal
• Others

Neuroendocrine Tumor Treatment Market in India by End Use [Analysis by Value from 2019 to 2031]:

• Hospital
• Clinic
• Others

Features of the Neuroendocrine Tumor Treatment Market in India

Market Size Estimates: Neuroendocrine tumor treatment in India market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends and forecasts by various segments.
Segmentation Analysis: Neuroendocrine tumor treatment in India market size by product, indication, and end use in terms of value ($B).
Growth Opportunities: Analysis of growth opportunities in different product, indication, and end use for the neuroendocrine tumor treatment in India.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the neuroendocrine tumor treatment in India.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q1. What are the major drivers influencing the growth of the neuroendocrine tumor treatment market in India?
Answer: The major drivers for this market are the growing prevalence of neuroendocrine cancer, the technological developments in the field of treating neuroendocrine tumors, and the increase in government programs.
Q2. What are the major segments for neuroendocrine tumor treatment market in India?
Answer: The future of the neuroendocrine tumor treatment market in India looks promising with opportunities in the hospital and clinic markets.
Q3. Which neuroendocrine tumor treatment market segment in India will be the largest in future?
Answer: Lucintel forecasts that somatostatin analogs (SSAs) are expected to witness the highest growth over the forecast period.
Q4. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 10 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the neuroendocrine tumor treatment market in India by product (somatostatin analogs (SSAs), targeted therapy, and chemotherapy), indication (lung, pancreas, gastrointestinal, and others), and end use (hospital, clinic, and others)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.4. What are the business risks and competitive threats in this market?
Q.5. What are the emerging trends in this market and the reasons behind them?
Q.6. What are some of the changing demands of customers in the market?
Q.7. What are the new developments in the market? Which companies are leading these developments?
Q.8. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.9. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.10. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Neuroendocrine Tumor Treatment Market in India, Neuroendocrine Tumor Treatment Market in India Size, Neuroendocrine Tumor Treatment Market in India Growth, Neuroendocrine Tumor Treatment Market in India Analysis, Neuroendocrine Tumor Treatment Market in India Report, Neuroendocrine Tumor Treatment Market in India Share, Neuroendocrine Tumor Treatment Market in India Trends, Neuroendocrine Tumor Treatment Market in India Forecast, Neuroendocrine Tumor Treatment Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.